Double-Drug attack on aggressive breast cancer before surgery
NCT ID NCT07054242
Summary
This study tests whether combining two drugs (SKB264 and pembrolizumab) given before surgery can eliminate cancer cells in patients with stage II-III triple-negative breast cancer. The trial will enroll 52 patients who haven't had previous cancer treatment to see if this combination leads to complete disappearance of cancer at surgery. Patients receive the drugs for several weeks, then undergo imaging and biopsies to check response before proceeding to surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Breast Surgery, Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.